FDA releases draft guidance to speed cell and gene therapy approvals

The FDA announced a draft guidance aimed at helping developers bring gene therapies to patients more quickly. It encourages use of publicly available scientific data and existing platform knowledge.

The guidance explains that sponsors can rely on existing chemistry, manufacturing and controls data, nonclinical study results, and clinical information to streamline regulatory submissions for human gene therapy products that employ genome editing in somatic cells.

Officials said the effort reflects the agency’s commitment to accelerate safe and effective cell and gene therapies, especially for rare and life‑threatening diseases with few treatment options, while maintaining rigorous scientific standards.